• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

外周动脉闭塞性疾病中使用组织型纤溶酶原激活剂进行动脉内溶栓的简化程序:初步和长期结果

A simplified procedure for intra-arterial thrombolysis with tissue-type plasminogen activator in peripheral arterial occlusive disease: primary and long-term results.

作者信息

Decrinis M, Pilger E, Stark G, Lafer M, Obernosterer A, Lammer J

机构信息

Department of Internal Medicine, Karl-Franzens-University School of Medicine Graz, Austria.

出版信息

Eur Heart J. 1993 Mar;14(3):297-305. doi: 10.1093/eurheartj/14.3.297.

DOI:10.1093/eurheartj/14.3.297
PMID:8458348
Abstract

One-hundred and fifty patients with thrombotic and 60 patients with embolic occlusions of the superficial femoral and/or popliteal artery underwent a simplified IAT (intra-arterial thrombolysis) procedure. Ten mg rt-PA combined with 3000 IU Heparin were infused over 6 h, thereafter the extent of thrombolysis was checked fluoroscopically and the above mentioned treatment course repeated up to four times if necessary. The IAT regimen employed did not involve mechanical recanalization attempts; if complete thrombolysis revealed an underlying stenosis, a PTA (percutaneous transluminal angioplasty) was subsequently performed. IAT resulted in complete recanalization of 88 thrombotic occlusions (59%; 95% confidence interval: 50.8%-66.8%) and of 53 embolic occlusions (88%; 95% confidence interval: 77.1%-94.8% P < 0.001). In a further 33 (22%) thrombotic and four (7%) embolic occlusions IAT reduced the length of the occluded segment. At discharge, 102 (67%) patients with thrombotic and 55 (92%) patients with embolic occlusions were clinically improved. Overall, untoward effects occurred in 60 patients (29%): 47 (22%) were minor. Four patients (2%) suffered a systemic haemorrhage (three gastrointestinal, one macrohaematuria). The cumulative potency rate was significantly higher in patients with embolic occlusions throughout follow-up (82% vs 49% for thrombotic occlusions at 2 years, P < 0.001). Although all amputations were carried out in patients with thrombotic occlusions, follow-up mortality did not differ significantly between patients with embolic and thrombotic occlusions.

摘要

150例股浅动脉和/或腘动脉血栓形成患者以及60例栓塞性闭塞患者接受了简化的动脉内溶栓(IAT)治疗。将10mg重组组织型纤溶酶原激活剂(rt-PA)与3000IU肝素混合,在6小时内输注,之后通过荧光镜检查溶栓程度,如有必要,上述治疗过程可重复进行多达4次。所采用的IAT方案不涉及机械再通尝试;如果完全溶栓后发现存在潜在狭窄,则随后进行经皮腔内血管成形术(PTA)。IAT使88例血栓性闭塞(59%;95%置信区间:50.8%-66.8%)和53例栓塞性闭塞(88%;95%置信区间:77.1%-94.8%,P<0.001)实现完全再通。在另外33例(22%)血栓性闭塞和4例(7%)栓塞性闭塞中,IAT缩短了闭塞段的长度。出院时,102例(67%)血栓形成患者和55例(92%)栓塞性闭塞患者的临床症状得到改善。总体而言,60例患者(29%)出现了不良反应:47例(22%)为轻微不良反应。4例患者(2%)发生了全身性出血(3例为胃肠道出血,1例为肉眼血尿)。在整个随访期间,栓塞性闭塞患者的累积有效率显著更高(2年时,栓塞性闭塞患者为82%,血栓性闭塞患者为49%,P<0.001)。虽然所有截肢手术均在血栓性闭塞患者中进行,但栓塞性闭塞患者和血栓性闭塞患者的随访死亡率并无显著差异。

相似文献

1
A simplified procedure for intra-arterial thrombolysis with tissue-type plasminogen activator in peripheral arterial occlusive disease: primary and long-term results.外周动脉闭塞性疾病中使用组织型纤溶酶原激活剂进行动脉内溶栓的简化程序:初步和长期结果
Eur Heart J. 1993 Mar;14(3):297-305. doi: 10.1093/eurheartj/14.3.297.
2
Efficacy and tolerance of recombinant tissue-type plasminogen activator in patients with thrombotic or embolic occlusions of leg-arteries.
Clin Investig. 1993 Apr;71(4):323-6. doi: 10.1007/BF00184736.
3
Retrospective analysis of Rt-pa thrombolysis combined with PGE1 in patients with peripheral arterial occlusions.瑞替普酶溶栓联合前列地尔治疗周围动脉闭塞症患者的回顾性分析
Angiology. 2000 May;51(5):377-84. doi: 10.1177/000331970005100504.
4
Comparison of tissue plasminogen activator and urokinase in the local infiltration thrombolysis of peripheral arterial occlusions.组织型纤溶酶原激活剂与尿激酶在外周动脉闭塞局部浸润溶栓中的比较。
Eur J Radiol. 1996 May;22(2):129-32. doi: 10.1016/0720-048x(96)00742-5.
5
[Simple and effective rt-PA thrombolysis design].[简单有效的重组组织型纤溶酶原激活剂溶栓设计]
Rofo. 1998 Nov;169(5):521-5. doi: 10.1055/s-2007-1015331.
6
Thrombolysis of acute peripheral arterial and venous occlusions with tenecteplase and eptifibatide: a pilot study.替奈普酶与依替巴肽用于急性外周动静脉闭塞溶栓治疗的初步研究
J Vasc Interv Radiol. 2003 Jun;14(6):729-33. doi: 10.1097/01.rvi.0000079981.80153.02.
7
Peripheral arterial occlusions: local low-dose thrombolytic therapy with recombinant tissue-type plasminogen activator (rt-PA).
Eur J Vasc Endovasc Surg. 1996 Jul;12(1):97-104. doi: 10.1016/s1078-5884(96)80283-8.
8
Fast-track thrombolysis protocol for acute limb ischemia.急性肢体缺血的快速溶栓方案。
J Vasc Surg. 2021 Mar;73(3):950-959. doi: 10.1016/j.jvs.2020.03.061. Epub 2020 May 11.
9
Can catheter-directed thrombolysis be applied to acute lower extremity artery embolism after recent cerebral embolism from atrial fibrillation?在近期发生心房颤动所致脑栓塞后,导管定向溶栓能否应用于急性下肢动脉栓塞?
Clin Radiol. 2008 Oct;63(10):1136-41. doi: 10.1016/j.crad.2008.04.014. Epub 2008 Jul 7.
10
Segmentally enclosed thrombolysis in percutaneous transluminal angioplasty for femoropopliteal occlusions: a report from a pilot study.经皮腔内血管成形术治疗股腘动脉闭塞症的节段性封闭溶栓:一项初步研究报告
Cardiovasc Intervent Radiol. 1991 Sep-Oct;14(5):293-8. doi: 10.1007/BF02578453.

引用本文的文献

1
Outcome and complications after intra-arterial thrombolysis for lower limb ischaemia with or without continuous heparin infusion.经动脉内溶栓治疗下肢缺血的疗效和并发症,有无持续肝素输注。
Br J Surg. 2014 Aug;101(9):1105-12. doi: 10.1002/bjs.9579. Epub 2014 Jun 25.
2
Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment.用于预防外周血管腔内治疗后再狭窄/再闭塞的抗血小板和抗凝药物。
Cochrane Database Syst Rev. 2012 Aug 15;2012(8):CD002071. doi: 10.1002/14651858.CD002071.pub3.
3
Antithrombotic treatment before and after peripheral artery percutaneous angioplasty.
外周动脉经皮血管成形术前后的抗栓治疗
Blood Transfus. 2009 Jan;7(1):18-23. doi: 10.2450/2008.0008-08b.
4
Thrombolytic treatment. Pulse spray infusion works faster but is more expensive.溶栓治疗。脉冲喷雾输注起效更快,但费用更高。
BMJ. 1995 Dec 2;311(7018):1505-6. doi: 10.1136/bmj.311.7018.1505d.